Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -81.82 is 85% above its 5-year average of -537.05, near the high end of its 5-year range (-1474.00–-81.82).
75.68% above its 12-month average of -336.50.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -21.32.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 31 comparable quarters.
EARNINGS PER SHARE (EPS)
-81.82
EARNINGS PER SHARE (EPS) AVG TTM
-336.50
EARNINGS PER SHARE (EPS) AVG 3Y
-753.63
EARNINGS PER SHARE (EPS) AVG 5Y
-537.05
EARNINGS PER SHARE (EPS) AVG 10Y
-338.95
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+75.68%
CURRENT VS 3Y AVG
+89.14%
CURRENT VS 5Y AVG
+84.77%
CURRENT VS 10Y AVG
+75.86%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
KALA BIO, Inc.
Market Cap
$7.16M
Earnings Per Share (EPS)
-81.82
TTM Avg
-336.50
3Y Avg
-753.63
5Y Avg
-537.05
Market Cap
$7.27M
Earnings Per Share (EPS)
-10.10
TTM Avg
-11.80
3Y Avg
-53.95
5Y Avg
-54.65
Market Cap
$6.98M
Earnings Per Share (EPS)
-1.16
TTM Avg
-3.29
3Y Avg
-3.69
5Y Avg
-2.95
Market Cap
$7.23M
Earnings Per Share (EPS)
-7.38
TTM Avg
-1.62
3Y Avg
-0.82
5Y Avg
-0.82
Market Cap
$7.25M
Earnings Per Share (EPS)
-3.48
TTM Avg
-5.74
3Y Avg
-24.14
5Y Avg
-2936.24
Market Cap
$6.99M
Earnings Per Share (EPS)
-16.00
TTM Avg
-9.75
3Y Avg
-5.91
5Y Avg
-4.74
Market Cap
$6.98M
Earnings Per Share (EPS)
-8.91
TTM Avg
-9.90
3Y Avg
-14.45
5Y Avg
-12.10
Market Cap
$6.75M
Earnings Per Share (EPS)
-26.72
TTM Avg
-36.23
3Y Avg
-30.51
5Y Avg
-16.78
Market Cap
$6.66M
Earnings Per Share (EPS)
-7.60
TTM Avg
-3746.91
3Y Avg
-66167.96
5Y Avg
-82548.30
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| KALA BIO, Inc. (KALA) | $7.16M | -81.82 | -336.50 | -753.63 | -537.05 |
| Longeveron Inc. (LGVN)vs › | $7.27M | -10.10 | -11.80 | -53.95 | -54.65 |
| Mangoceuticals, Inc. (MGRX)vs › | $6.98M | -1.16 | -3.29 | -3.69 | -2.95 |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.23M | -7.38 | -1.62 | -0.82 | -0.82 |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.25M | -3.48 | -5.74 | -24.14 | -2936.24 |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.99M | -16.00 | -9.75 | -5.91 | -4.74 |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $6.98M | -8.91 | -9.90 | -14.45 | -12.10 |
| Co-Diagnostics, Inc. (CODX)vs › | $6.75M | -26.72 | -36.23 | -30.51 | -16.78 |
| Aclarion, Inc. (ACON)vs › | $6.66M | -7.60 | -3746.91 | -66167.96 | -82548.30 |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.50M | -16.46 | -132.36 | -129.45 | -404.68 |
Trailing EPS (TTM)
$-81.82
Forward EPS (Est.)
$-26.50
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -165.50 |
| 2024-12-31 | -507.50 |
| 2023-12-31 | -867.50 |
| 2022-12-31 | -1474.00 |
| 2021-12-31 | -108.32 |
| 2020-12-31 | -99.50 |
| 2019-12-31 | -138.00 |
| 2018-12-31 | -124.73 |
| 2017-12-31 | -99.20 |
| 2016-12-31 | -95.95 |
| 2015-12-31 | -48.26 |
| 2014-12-31 | -40.03 |
| 2013-12-31 | -22.03 |
